betaas3-fb vector transduced bm cd34+ cells
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2014 (NCT02247843)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- ErythrocyteSupplementation
Erythrocyte supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- betaas3-fb vector transduced bm cd34+ cells
- βas3-fb vector transduced bm cd34+ cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02247843 | Phase 1 | Jul 1, 2014 | California Institute for Regenerative Medicine, University of California, Los Angeles, University of Southern California |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| California Institute for Regenerative Medicine | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1